Phase III trial shows Gileyna significantly reduces relapses in children and adolescents with MS
A phase III Paradigms study in paediatric multiple sclerosis (MS) has met its primary end point, showing a significant reduction in the occurrence of relapses with Gileyna (also known as fingolimod) versus interferon beta-1a...Read more - http://www.ms-uk.org/phase-iii-trial-sh ... escents-ms
Gileyna significantly reduces relapses in children...
Gileyna significantly reduces relapses in children...
MS-UK - http://www.ms-uk.org/
Re: Gileyna significantly reduces relapses in children...
But does it reduce progression of disability? That's what really counts.MSUK wrote:Phase III trial shows Gileyna significantly reduces relapses in children and adolescents with MS
A phase III Paradigms study in paediatric multiple sclerosis (MS) has met its primary end point, showing a significant reduction in the occurrence of relapses with Gileyna (also known as fingolimod) versus interferon beta-1a...Read more - http://www.ms-uk.org/phase-iii-trial-sh ... escents-ms
-
- Similar Topics
- Replies
- Views
- Last post